These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32592377)

  • 21. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
    Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
    Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
    Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
    Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
    Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
    PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
    Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
    Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.
    Yeramian A; Vea A; Benítez S; Ribera J; Domingo M; Santacana M; Martinez M; Maiques O; Valls J; Dolcet X; Vilella R; Cabiscol E; Matias-Guiu X; Marti RM
    Pigment Cell Melanoma Res; 2016 May; 29(3):352-71. PubMed ID: 26988132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.
    Gökşen Tosun N
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3249-3259. PubMed ID: 37917369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations.
    Ho KT; Chen PF; Chuang JY; Gean PW; Hsueh YS
    Life Sci; 2022 Jan; 288():120176. PubMed ID: 34848192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
    Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
    Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.
    Lee KH; Lee JH; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Cancer Sci; 2011 Jul; 102(7):1388-95. PubMed ID: 21453385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
    Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
    J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
    Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
    Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
    Stühmer T; Zöllinger A; Siegmund D; Chatterjee M; Grella E; Knop S; Kortüm M; Unzicker C; Jensen MR; Quadt C; Chène P; Schoepfer J; García-Echeverría C; Einsele H; Wajant H; Bargou RC
    Leukemia; 2008 Aug; 22(8):1604-12. PubMed ID: 18480838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.